Full Breakdown
Nationwide Recall of Compounded GLP-1 Injections Highlights Sterility Issues
By Drooid · · How we work
Core Event: Recall of Compounded Tirzepatide Products
Compounding pharmacy Houston RX LLC recalled 64 vials of tirzepatide-niacinamide (20 mg/2 mg per mL) after the FDA determined the batch lacked assurance of sterility. The agency classified the action as a Class II recall, indicating that use could cause temporary or medically reversible health problems, though serious harm is unlikely. A separate voluntary recall by Apothecary Pharma LLC involved 22 vials of tirzepatide, also designated Class II. Both recalls were announced in September 2026.
Background & Context: Compounding Pharmacies and GLP-1 Demand
Compounding pharmacies create customized drug formulations from raw ingredients, often to address dose adjustments, allergen removal, or drug shortages. During the 2022 shortage of GLP-1 weight-loss agents, the FDA granted temporary permission for compounders to produce tirzepatide and semaglutide in bulk. After the drugs were removed from the official shortage list in late 2024 and early 2025, many compounders continued large-scale production, supplying patients through telehealth platforms. Unlike mass-produced pharmaceuticals, compounded formulations are not evaluated by the FDA for purity, safety, or effectiveness, and they are not routinely regulated, a situation that has previously led to contamination incidents such as the 2012 New England Compounding Center fungal meningitis outbreak.
Data & Statistics
- Recall quantities: 64 vials (Houston RX) and 22 vials (Apothecary Pharma).
- Adverse event reports: As of May 31 2026, the FDA’s unapproved GLP-1 database recorded 990 reports linked to compounded semaglutide and more than 730 reports linked to compounded tirzepatide.
- Inspection findings (Houston RX): Federal inspectors documented 14 observations, including exposed hair or skin during aseptic work, negative pressure differentials between clean-room zones, microbial growth in an ISO 5 hood, unsterilized equipment, water-stained vent with possible mold, and use of research-grade or dietary-supplement-grade ingredients.
- Pricing pressure: A price survey released by telehealth company NexLife indicated a median monthly cost of $222 for compounded tirzepatide and $175 for compounded semaglutide across multiple online programs.
Official Statements & Responses
The agency’s Form 483 inspection report clarified that the observations do not constitute a final determination of non-compliance; the pharmacy may respond or correct the deficiencies. No public response from Houston RX was located. The FDA’s page on unapproved GLP-1 drugs notes that adverse-event reports are likely under-reported and that the reports alone do not prove causation.
Verbatim Quotes
- “Personnel performed aseptic manipulations with exposed hair or skin.” — Inspectors
Why It Matters
Compounded GLP-1 injections fill a market gap created by high demand and insurance coverage limitations, but the lack of FDA approval and routine oversight raises safety concerns. Sterility failures can lead to injection-site infections or bloodstream contamination, conditions that patients may not detect without medical evaluation. The recalls also underscore ongoing legal pressure from pharmaceutical manufacturers such as Eli Lilly and Novo Nordisk, who have sued compounders to limit the practice.
Conflicting Reports & Gaps
Sources differ on the total number of tirzepatide vials recalled. One report cites a recall of 22 vials nationwide, while another details a recall of 64 vials from Houston RX. Both recalls are classified as Class II, but the discrepancy highlights a gap in publicly consolidated recall data. No illnesses have been publicly linked to the recalled vials, and the FDA’s adverse-event database does not attribute specific harms to the recalled batches.
Patients with affected prescriptions are advised to verify the pharmacy name on the vial label, consult their prescriber, and report any injection-site reactions to the FDA’s MedWatch program.